Oncology DRUG REPORT
providing intelligence at fingertips
Worldwide 34 Countries Covered. Largest Coverage Guaranteed
1009 Active Clinical & 1001 Preclinical Stage Oncology Companies ProfiledÂ
Individual Drug Mechanism of Action & Drug Target
Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies
Intelligence @ fingertips
Provides Complete Landscape on Latest Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status in the Domain.
Drug Developers with proper funding, technologies and pipeline are only included.
No Acquired, Merged or Dormant Stage Cancer Targeting Drug Developer is included.
identify new opportunities
Unique first in class Intelligence Report
Comparisons | Oncology Drug Report 2021 | Other Intelligence Sources |
|---|---|---|
Clinical Stage Oncology Drug Developers | 1009 Active Companies (Companies with Active Pipeline are only Included) | 600-800 Companies (maybe mixed with non active/ diagnostic etc.) |
Pre-Clinical Stage Oncology Drug Developers | 1001 Active Companies (Well Funded with clear defined early stage Pipeline) | 400-600 Companies (with many inactive and other domain companies) |
Worldwide Coverage | 34 Countries Included (52% USA, 24% Europe, 20% Asia and 4% ROW) | Mainly United States and Europe Covered |
Oncology Drugs in Development | 3500+ Onco Targeting Drugs in Active Development(2300+ Clinical Stage with NCT Number & 1200+ Preclinical Stage, with their Targets and mechanism of Action) | 2000 – 2500 Onco Targeting Drugs (mainly includes Clinical Stage molecules in development) |
Bio-Partnering Details | 1100+ Oncology Deals complete details.(Complete coverage on Oncology focused Deals, Funding & Partnering Activities, since company’s incorporation) | Limited to Database / Resource Subscribed to.(Also it may require mapping of events between two or more different resources and filtering Onco Linked Deals). |
Trusted by
